no desc

Chronic Venous Insufficiency, Cardiovascular Disease and Mortality

The aim of this study was to obtain evidence regarding the health burden of chronic venous insufficiency (CVI), its clinical determinants, and its impact on the outcome.

Systematic phenotyping of CVI according to established CEAP classification was performed in 12,423 participants (age range: 40–80 years) of the Gutenberg Health Study from April 2012 to April 2017. Prevalence was calculated to age- and sex-specifically. Multivariable Poisson regression models were calculated to evaluate the relation of CVI with cardiovascular comorbidities. Survival analyses were carried out to assess the CVI-associated risk of death. Replication of findings was done in an independent cohort study (MyoVasc).

The prevalence of telangiectasia/reticular, varicose veins, and CVI was 36.5% [95% confidence interval (CI), 35.6–37.4%], 13.3% [12.6–13.9%], and 40.8% [39.9–41.7%], respectively. Age, female sex, arterial hypertension, obesity, smoking, and clinically overt cardiovascular disease were identified as clinical determinants of CVI. Higher CEAP classes were associated with a higher predicted 10-year risk for incident cardiovascular disease in individuals free of cardiovascular disease (n = 9923). During a mean follow-up of 6.4 ± 1.6 years, CVI was a strong predictor of all-cause death independent of the concomitant clinical profile and medication. The association of CVI with an increased risk of all-cause death was externally validated in the MyoVasc cohort.

The study concludes that CVI is highly prevalent in the population and is associated with the presence of cardiovascular risk factors and disease. Individuals with CVI experience an elevated risk of death, which is independent of age and sex, and present cardiovascular risk factors and comorbidities.

no desc

To know more : Click here

It can also interest you


January 7, 2022
The "self-treatment of wounds for venous leg ulcers checklist“ – Do you know th…
Venous disease


January 17, 2022
Proven efficacy of the Micronized Purified Flavonoid Fraction (MPFF) on chronic…
Venous disease


January 31, 2022
Superior pain relief in Chronic Venous Disease patients undergoing after endove…
Venous disease
Background Vimeo Live Event

Keep up to date with our content

Subscribe to our newsletter so that you are always up to date with the news.

You can unsubscribe at any time by clicking on the link in our emails.
SERVIER CENTRAL AMERICA AND THE CARIBBEAN, S.A.Edificio Dream Plaza, Costa Del Este, Ciudad de Panamá, Panamá+507-301-0227Todo el contenido de este sitio web, es sólo para los profesionales de la salud y un uso interno del evento.
LogoCopyright © 2022 Servier University by SERVIER CENTRO AMÉRICA Y EL CARIBE, S.A.